Innate Pharma SA
OTC:IPHYF
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
I
|
Innate Pharma SA
OTC:IPHYF
|
FR |
|
Kinross Gold Corp
TSX:K
|
CA |
|
Fujitsu General Ltd
TSE:6755
|
JP |
|
Alliant Energy Corp
NASDAQ:LNT
|
US |
|
B
|
Bayan Resources Tbk PT
XBER:BNB
|
ID |
Wall St Price Targets
IPHYF Price Targets Summary
Innate Pharma SA
According to Wall Street analysts, the average 1-year price target for IPHYF is 5.56 USD with a low forecast of 4.63 USD and a high forecast of 6.63 USD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is IPHYF's stock price target?
Price Target
5.56
USD
According to Wall Street analysts, the average 1-year price target for IPHYF is 5.56 USD with a low forecast of 4.63 USD and a high forecast of 6.63 USD.
What is the Revenue forecast for Innate Pharma SA?
Projected CAGR
92%
Over the last 14 years, the compound annual growth rate for Revenue has been -7%. The projected CAGR for the next 7 years is 92%.
What is the Gross Profit forecast for Innate Pharma SA?
Projected CAGR
1 086%
The compound annual growth rate for Gross Profit over the next 3 years is 1 086%.
